Cinclus Pharma says Phase 1 studies show rapid, sustained acid control with linaprazan glurate

PUBT · 2d ago
Cinclus Pharma says Phase 1 studies show rapid, sustained acid control with linaprazan glurate
  • Cinclus Pharma reported published Phase 1 results for linaprazan glurate in Alimentary Pharmacology & Therapeutics.
  • Results were already presented via publication, not flagged for a future medical meeting.
  • Studies showed rapid, sustained stomach acid control at higher doses, supporting continued development for erosive GERD.
  • A separate Phase 1 formulation study found the Phase III tablet delivers higher drug exposure than an earlier version.
  • The company framed the findings as supportive of its late-stage strategy, with Phase III having started in 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cinclus Pharma Holding AB (Publ) published the original content used to generate this news brief on October 05, 2026, and is solely responsible for the information contained therein.